nrf2-activators-parkinsons-disease

NRF2 Activators for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">nrf2-activators-parkinsons-disease</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>NRF2 (NFE2L2) / KEAP1 Pathway</td>
</tr>
<tr>
<td class="label">Development Stage</td>
<td>Phase I-II</td>
</tr>
<tr>
<td class="label">Route of Administration</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Key Compounds</td>
<td>Sulforaphane, Dimethyl fumarate, Bardoxolone methyl</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">MPTP model</td>
<td>40-60% dopaminergic neuron protection</td>
</tr>
<tr>
<td class="label">6-OHDA model</td>
<td>35-45% neurodegeneration attenuation</td>
</tr>
<tr>
<td class="label">Alpha-synuclein overexpression</td>
<td>Enhanced autophagic clearance of α-synuclein</td>
</tr>
<tr>
<td class="label">Drosophila PD model</td>
<td>Extended lifespan, preserved climbing ability</td>
</tr>
<tr>
<td class="label">Population</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Early PD</td>
<td>100-200 μmol/day (~17-35 mg SFN)</td>
</tr>
<tr>
<td class="label">Prodromal</td>
<td>40-100 μmol/day</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT04550494</td>
<td>Phase II</td>
</tr>
<tr>
<td class="l

NRF2 Activators for Parkinson's Disease

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">nrf2-activators-parkinsons-disease</th>
</tr>
<tr>
<td class="label">Category</td>
<td>Disease-Modifying Therapy</td>
</tr>
<tr>
<td class="label">Target</td>
<td>NRF2 (NFE2L2) / KEAP1 Pathway</td>
</tr>
<tr>
<td class="label">Development Stage</td>
<td>Phase I-II</td>
</tr>
<tr>
<td class="label">Route of Administration</td>
<td>Oral</td>
</tr>
<tr>
<td class="label">Key Compounds</td>
<td>Sulforaphane, Dimethyl fumarate, Bardoxolone methyl</td>
</tr>
<tr>
<td class="label">Model</td>
<td>Finding</td>
</tr>
<tr>
<td class="label">MPTP model</td>
<td>40-60% dopaminergic neuron protection</td>
</tr>
<tr>
<td class="label">6-OHDA model</td>
<td>35-45% neurodegeneration attenuation</td>
</tr>
<tr>
<td class="label">Alpha-synuclein overexpression</td>
<td>Enhanced autophagic clearance of α-synuclein</td>
</tr>
<tr>
<td class="label">Drosophila PD model</td>
<td>Extended lifespan, preserved climbing ability</td>
</tr>
<tr>
<td class="label">Population</td>
<td>Dose</td>
</tr>
<tr>
<td class="label">Early PD</td>
<td>100-200 μmol/day (~17-35 mg SFN)</td>
</tr>
<tr>
<td class="label">Prodromal</td>
<td>40-100 μmol/day</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NCT04550494</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Standard dose</td>
<td>120-240 mg BID</td>
</tr>
<tr>
<td class="label">Brain penetration</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>~1 hour (MMF)</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">STOP-AD</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">FUMADERMA</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">NCT05237570</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Dose</td>
<td>150-300 mg daily</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>Good</td>
</tr>
<tr>
<td class="label">Brain penetration</td>
<td>Limited</td>
</tr>
<tr>
<td class="label">Compound</td>
<td>Development Stage</td>
</tr>
<tr>
<td class="label">Sulforaphane</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Dimethyl fumarate</td>
<td>Phase II</td>
</tr>
<tr>
<td class="label">Bardoxolone methyl</td>
<td>Phase I</td>
</tr>
<tr>
<td class="label">Biomarker</td>
<td>Measurement</td>
</tr>
<tr>
<td class="label">NRF2 target gene expression</td>
<td>qPCR (HO-1, NQO1, GCLM)</td>
</tr>
<tr>
<td class="label">GSH/GSSG ratio</td>
<td>HPLC</td>
</tr>
<tr>
<td class="label">8-OHdG</td>
<td>ELISA</td>
</tr>
<tr>
<td class="label">8-isoprostane</td>
<td>ELISA</td>
</tr>
<tr>
<td class="label">NQO1 expression in PBMCs</td>
<td>Flow cytometry</td>
</tr>
<tr>
<td class="label">Combination</td>
<td>Rationale</td>
</tr>
<tr>
<td class="label">NRF2 + [CoQ10](/therapeutics/coq10-parkinsons)</td>
<td>Synergistic mitochondrial protection</td>
</tr>
<tr>
<td class="label">NRF2 + [GLP-1 agonists](/therapeutics/glp-1-receptor-agonists-parkinsons)</td>
<td>Complementary neuroprotection</td>
</tr>
<tr>
<td class="label">NRF2 + exercise</td>
<td>Enhanced Nrf2 activation</td>
</tr>
</table>

Overview

Pathway / Mechanism Diagram

Therapeutic Rationale

The [NRF2](/genes/nrf2) (Nuclear Factor Erythroid 2-Related Factor 2) pathway is the master regulator of cellular antioxidant responses and represents a promising therapeutic target for [Parkinson's disease](/diseases/parkinsons-disease). Under normal conditions, NRF2 is bound by KEAP1 and targeted for degradation. Upon oxidative stress, NRF2 is released, translocates to the nucleus, and activates the antioxidant response element (ARE), driving expression of over 200 cytoprotective genes[@cuadrado2024].

In PD, NRF2 activity is impaired, leading to inadequate antioxidant responses and increased vulnerability to [oxidative stress](/mechanisms/oxidative-stress-parkinsons). Post-mortem studies show reduced NRF2 nuclear localization in dopaminergic neurons of PD patients, suggesting that restoring NRF2 function could provide significant neuroprotection.

Key Therapeutic Compounds

Sulforaphane

Sulforaphane is a naturally occurring isothiocyanate derived from the hydrolysis of glucoraphanin, found at high concentrations in broccoli sprouts. It is the most potent naturally occurring inducer of NRF2[@bahr2020].

Mechanism of Action

Sulforaphane activates NRF2 through covalent modification of KEAP1 cysteine residues (Cys151, Cys273, Cys288), leading to NRF2 release and nuclear translocation. This triggers transcription of:

• HO-1 (Heme oxygenase-1): Anti-inflammatory, neuroprotective
• NQO1 (NAD(P)H quinone oxidoreductase 1): Antioxidant defense
• GCLM (Glutamate-cysteine ligase modifier): Increases glutathione synthesis
• SOD1/2 (Superoxide dismutase): Neutralizes superoxide radicals

Preclinical Evidence in PD

Clinical Trials

• REST trial (NCT05084365): Phase I/II randomized trial of broccoli sprout extract in early PD
• SFN-GBA trial (NCT03794592): Phase II in PD patients with GBA mutations

Dosing

Safety Profile

• Common: GI upset, flatulence, sulfurous eructation (10-20%)
• Rare: Thyroid effects at extreme doses
• Contraindications: Cruciferous vegetable allergy

Dimethyl Fumarate (DMF)

Dimethyl fumarate (Tecfidera) is FDA-approved for multiple sclerosis and is being repurposed for PD. It activates NRF2 through KEAP1 cysteine modification[@davies2022].

Mechanism of Action

DMF and its metabolite monomethyl fumarate (MMF) modify KEAP1 cysteine residues, releasing NRF2 for nuclear translocation and ARE-dependent gene transcription.

Clinical Evidence

Dosing

Side Effects

• Flushing (common)
• GI symptoms (nausea, diarrhea)
• Lymphopenia (monitor CBC)

Bardoxolone Methyl (CDDO-Me)

Bardoxolone methyl is a synthetic triterpenoid that potently activates NRF2. It has been evaluated in neurodegenerative diseases including AD (STOP-AD trial)[@kavanagh2024].

Mechanism of Action

Bardoxolone methyl is a highly electrophilic compound that covalently modifies KEAP1 cysteines, producing robust NRF2 activation. It also directly inhibits NF-κB, providing additional anti-inflammatory effects.

Clinical Trials

Dosing

Side Effects

• Liver enzyme elevation
• GI symptoms
• Proteinuria (monitor renal function)

Comparison of NRF2 Activators for PD

Biomarkers for Target Engagement

Combination Therapy Approaches

NRF2 activators can be combined with other disease-modifying approaches:

Challenges and Limitations

Future Directions

• Development of brain-penetrant NRF2 activators with improved pharmacokinetics
• Combination therapy with other disease-modifying approaches
• Biomarker development for patient stratification and response monitoring
• Gene therapy approaches for sustained NRF2 activation

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [NRF2 in PD](/mechanisms/nrf2-parkinsons-disease)
• [Oxidative Stress in PD](/mechanisms/oxidative-stress-parkinsons)
• [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-parkinsons)
• [DJ-1 Pathway](/therapeutics/park7-dj1-therapy-parkinsons)
• [Sulforaphane Nrf2 Neuroprotection](/therapeutics/sulforaphane-nrf2-neuroprotection)
• [NRF2 Activators for Neurodegeneration](/therapeutics/nrf2-activators-neurodegeneration)

References

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Matrix Stiffness Normalization via Targeted Lysyl Oxidase Inhibition](/hypothesis/h-82922df8) — <span style="color:#81c784;font-weight:600">0.69</span> · Target: LOX/LOXL1-4
• [Sphingomyelin Synthase Activators for Raft Remodeling](/hypothesis/h-fdb07848) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: SGMS1/SGMS2

Related Analyses:

• [Lipid raft composition changes in synaptic neurodegeneration](/analysis/SDA-2026-04-01-gap-lipid-rafts-2026-04-01) &#x1f504;